Osteoporosis Medications 2026: Which Treatment Is Right for Seniors?

If you have been diagnosed with osteoporosis, choosing the right medication in 2026 is one of the most important decisions you and your doctor will make. With six distinct drug classes now available—each working through different mechanisms, with different fracture reduction rates, and different Medicare coverage rules—this is not a one-size-fits-all decision. As a senior health specialist, I have seen patients dramatically reduce their fracture risk by matching treatment to their individual risk profile. Here is the expert-level guide you need.

Table of Contents

• Who Needs Osteoporosis Medication?
• Bisphosphonates: The First-Line Standard
• Denosumab (Prolia): Twice-Yearly Injection
• Romosozumab (Evenity): Dual-Action 12-Month Treatment
• Anabolic Agents: Forteo and Tymlos
• Medication Comparison Table
• How to Sequence Treatments Correctly
• Medicare Coverage for Osteoporosis Drugs
• Frequently Asked Questions

Who Needs Osteoporosis Medication?

Not every senior with a low bone density scan needs medication immediately. The 2022 American Society for Bone and Mineral Research (ASBMR) guidelines recommend pharmacologic treatment for adults who meet any of the following criteria: a hip or spine T-score of −2.5 or lower on DEXA scan; a prior low-trauma hip or vertebral fracture; or a FRAX 10-year probability score of ≥3% for hip fracture or ≥20% for major osteoporotic fracture. The FRAX tool (frax.shef.ac.uk) integrates age, sex, BMI, fracture history, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis to produce an individualized fracture probability—making it far more actionable than a T-score alone.

Equally important: roughly 54 million Americans have osteoporosis or low bone mass (osteopenia), yet only 30% of eligible seniors receive appropriate pharmacologic therapy according to the Bone Health and Osteoporosis Foundation (BHOF). This treatment gap costs Medicare an estimated $30 billion annually in hip fracture care.

Bisphosphonates: The First-Line Standard

Bisphosphonates remain the first-line treatment for most seniors with osteoporosis. They inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inducing osteoclast apoptosis. Four options are widely used:

• Alendronate (Fosamax): 70 mg oral tablet once weekly. The landmark FIT trial (N Engl J Med, 1996; n=2,027) demonstrated a 47% reduction in vertebral fractures and a 51% reduction in hip fractures over 3 years. Generic cost: under $10/month.
• Risedronate (Actonel): 35 mg once weekly or 150 mg once monthly. The HIP trial showed a 30% reduction in hip fractures in women with confirmed femoral neck osteoporosis. Preferred for seniors with esophageal issues.
• Ibandronate (Boniva): 150 mg oral monthly or 3 mg IV every 3 months. Reduces vertebral fractures 50-62% (BONE trial); limited hip fracture data. Less preferred as first-line.
• Zoledronic acid (Reclast): 5 mg IV infusion once yearly. The HORIZON-PFT trial (N Engl J Med, 2007; n=7,765) showed a 70% reduction in vertebral fractures, 41% in hip fractures, and—uniquely—a 28% reduction in all-cause mortality when given within 90 days of hip fracture repair. Ideal for seniors with GI intolerance to oral bisphosphonates.

Bisphosphonate Side Effects Seniors Must Know

The most common side effect is upper GI irritation with oral bisphosphonates. To minimize this, take on an empty stomach with 8 oz of water and remain upright for 30-60 minutes. More rare but serious adverse effects include atypical femur fractures (incidence 3.2-50 per 100,000 patient-years—highest risk after 5+ years of continuous use) and osteonecrosis of the jaw (ONJ), occurring in fewer than 1 in 10,000 patients treated for osteoporosis (risk is much higher in cancer patients receiving high-dose IV bisphosphonates). A drug holiday after 3-5 years may be appropriate if T-score improves to above −2.5; this decision requires physician guidance.

Denosumab (Prolia): Twice-Yearly Injection

Denosumab (Prolia) is a monoclonal antibody that inhibits RANKL, a protein essential for the development and survival of bone-dissolving osteoclasts. Administered as a 60 mg subcutaneous injection every 6 months, it is particularly useful when oral bisphosphonates are not tolerated, in patients with chronic kidney disease (eGFR 15-29 mL/min—where bisphosphonates are contraindicated), or when superior hip fracture reduction is needed.

The FREEDOM trial (3-year, n=7,808) established denosumab’s efficacy benchmark: a 68% reduction in vertebral fractures, 40% reduction in hip fractures, and 20% reduction in non-vertebral fractures vs placebo. Long-term FREEDOM extension data at 10 years confirmed continued bone mineral density gains without a plateau—something not seen with bisphosphonates.

The critical clinical caveat: stopping denosumab without transitioning to a bisphosphonate causes rapid rebound bone loss and a cluster of vertebral fractures within 12-24 months. This is not a drug holiday—it is a treatment risk. If a patient must stop denosumab (due to jaw surgery, infection, cost), zoledronic acid 5 mg IV must be given within 6 months of the last Prolia injection to prevent rebound fractures. Medicare Part B covers Prolia as a physician-administered injection at 80% of the allowed amount after the Part B deductible.

Romosozumab (Evenity): Dual-Action 12-Month Treatment

Romosozumab (Evenity) is a monoclonal antibody that blocks sclerostin, a protein produced by osteocytes that inhibits bone formation. By neutralizing sclerostin, romosozumab simultaneously stimulates bone formation AND inhibits bone resorption—a unique dual mechanism that sets it apart from all other osteoporosis medications. It is administered as 210 mg (two 105 mg injections) subcutaneously once monthly for exactly 12 months, after which treatment must transition to an antiresorptive agent.

The ARCH trial (n=4,093, N Engl J Med, 2017) compared romosozumab followed by alendronate vs alendronate alone: 48% lower risk of new vertebral fractures and 19% fewer major osteoporotic fractures at 24 months. The FRAME trial showed a 73% lower vertebral fracture risk vs placebo. Critically, the ARCH trial also identified a higher rate of cardiovascular events (MI and stroke) in the romosozumab group—leading to an FDA black-box warning. Romosozumab is contraindicated in seniors with a myocardial infarction or stroke within the prior 12 months. A careful cardiovascular risk discussion with your cardiologist is essential before starting this medication.

Anabolic Agents: Forteo and Tymlos

Two parathyroid hormone analog medications actually build new bone rather than simply slowing loss—making them uniquely powerful for seniors with very severe osteoporosis or multiple prior fractures.

Teriparatide (Forteo): A recombinant PTH(1-34) fragment given as 20 mcg subcutaneous injection daily for up to 24 months. The landmark NEER trial (N Engl J Med, 2001; n=1,637) demonstrated a 65% reduction in vertebral fractures and 53% reduction in non-vertebral fractures vs placebo. The FDA required a black-box warning based on osteosarcoma seen in rats at supratherapeutic doses; however, more than 20 years of post-marketing surveillance in millions of patients has not confirmed elevated osteosarcoma risk in humans. Medicare Part D covers Forteo; retail cost exceeds $25,000/year without coverage.

Abaloparatide (Tymlos): A PTH-related protein analog given as 80 mcg daily SC injection for 18-24 months. The ACTIVE trial (n=2,463) demonstrated an 86% lower relative risk of vertebral fractures vs placebo—the highest published fracture reduction rate of any osteoporosis medication. It has a somewhat better tolerability profile than teriparatide (less orthostatic hypotension). Both anabolic agents MUST be followed by an antiresorptive agent (bisphosphonate or denosumab) to consolidate bone gains; without this transition, 50-80% of gained bone is lost within 2 years.

Osteoporosis Medication Comparison Table 2026

How to Sequence Osteoporosis Treatments Correctly

Treatment sequencing matters as much as medication selection. The ASBMR 2022 guidelines and the BHOF 2022 Clinical Practice Guidelines both recommend a risk-stratified approach:

• Low-to-moderate risk (T-score between −1.0 and −2.5, no prior fracture, FRAX <20%): Anti-resorptives first—oral bisphosphonate is most cost-effective.
• High risk (T-score ≤−2.5 or prior low-trauma fracture): Begin with bisphosphonate or denosumab; reassess in 3-5 years.
• Very high risk (T-score ≤−3.0 OR multiple fractures OR fracture on bisphosphonate therapy): Start with an anabolic agent (teriparatide, abaloparatide, or romosozumab), then sequence to a bisphosphonate to consolidate bone gains. Sequential therapy in this order produces superior outcomes compared to starting with bisphosphonates.
• Denosumab → bisphosphonate transition is mandatory, not optional. This is the most commonly missed clinical step in osteoporosis management.

Calcium (1,200 mg/day from food + supplements combined) and Vitamin D3 (800-1,000 IU/day; aim for serum 25-OH vitamin D of 30-50 ng/mL) are foundational adjuncts for all patients on osteoporosis medication. Resistance exercise and fall prevention strategies—including balance training and home safety modifications—are equally critical to fracture prevention outcomes.

What Medicare Covers for Osteoporosis Medications in 2026

Medicare coverage depends on how the medication is administered. Understanding which part covers your drug prevents surprise bills:

• Part B (covers 80% after $283 deductible): Zoledronic acid IV (Reclast), denosumab injections (Prolia) given in physician office, romosozumab (Evenity) when administered by a provider. Part B also covers bone density (DEXA) scans every 24 months for eligible seniors.
• Part D (covers per plan formulary): Oral bisphosphonates (generic alendronate typically Tier 1-2, very low copay), teriparatide (Forteo), abaloparatide (Tymlos). The 2026 Part D $2,100 out-of-pocket cap significantly reduces costs for expensive injectables like Forteo.
• Medigap Plan G: Covers the 20% Part B coinsurance for physician-administered injections.

For seniors on Medicare Advantage, prior authorization requirements vary by plan. Always confirm formulary coverage before your physician prescribes a specific agent—and if denied, use the Medicare appeal process: peer-to-peer review overturns roughly 50-70% of initial denials.

Frequently Asked Questions

How long do I need to take osteoporosis medication?

Duration depends on the specific medication and your ongoing fracture risk. Most guidelines recommend reassessing after 3-5 years for bisphosphonates: if T-score has improved to above −2.5 and you have no prior hip fracture, a drug holiday of 1-3 years may be appropriate. Denosumab, however, requires continuous treatment or a carefully managed transition—stopping it abruptly risks a rebound cluster of vertebral fractures. Anabolic agents (Forteo, Tymlos, Evenity) are time-limited treatments that must always be followed by an antiresorptive agent.

Can I take osteoporosis medication if I have kidney disease?

Kidney function is a critical prescribing consideration. Oral bisphosphonates are generally contraindicated when eGFR is below 30-35 mL/min due to risk of accumulation and nephrotoxicity. Zoledronic acid IV is also typically avoided below eGFR 35. Denosumab (Prolia) is the preferred option for seniors with CKD Stages 3-5 and even dialysis patients, though hypocalcemia monitoring is essential. Your nephrologist and primary care physician should coordinate on the best choice.

Are there natural alternatives to osteoporosis medications?

No supplement or lifestyle intervention has been shown to reduce fracture risk in patients who already meet pharmacologic treatment thresholds. Calcium and Vitamin D are essential adjuncts but do not replace medication in high-risk individuals. Weight-bearing exercise and resistance training preserve bone density and reduce fall risk, but the fracture reduction documented in clinical trials (40-70%) is only achievable with pharmacotherapy. Discuss your individual FRAX score and T-score with your physician before declining medication based on lifestyle measures alone.

What is the difference between Prolia and Evenity?

Both are injectable monoclonal antibodies but with fundamentally different mechanisms. Prolia (denosumab) only inhibits bone resorption and is given indefinitely every 6 months. Evenity (romosozumab) both builds new bone AND slows resorption—but is limited to exactly 12 monthly injections, carries a cardiovascular black-box warning, and must be followed by a bisphosphonate. Evenity is typically reserved for very high-risk patients (recent fracture, T-score ≤−3.0) without recent cardiac events; Prolia is used more broadly including in CKD patients who cannot take bisphosphonates.

Does Medicare cover a bone density (DEXA) scan?

Yes. Medicare Part B covers bone density (DEXA) measurements every 24 months for women who are estrogen-deficient and at clinical risk for osteoporosis; individuals whose X-rays show vertebral abnormalities; individuals receiving or planning to receive long-term glucocorticoid therapy; individuals with primary hyperparathyroidism; and individuals being monitored to assess response to osteoporosis therapy. You pay 20% of the Medicare-approved amount after your Part B deductible.

Related Articles You May Find Helpful

• Hip Fractures in Seniors 2026: Prevention, Recovery & Medicare Coverage
• Balance Exercises for Seniors Over 70: 8 Proven Moves to Prevent Falls
• Arthritis Pain Relief for Seniors 2026: What Actually Works
• Polypharmacy in Seniors 2026: When 5+ Medications Become Dangerous
• Senior Health Conditions 2026: Expert Guide to Prevention & Treatment

Sources

• Medicare.gov: Bone Density Measurement Coverage
• Bone Health and Osteoporosis Foundation (BHOF) 2022 Clinical Practice Guidelines
• NIH NIAMS: Osteoporosis Overview